Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trial
| Autor: | Yan, Xiang, Ma, Jianhua, Liu, Yan, Wang, Xuhong, Li, Sheli, Yan, Shuang, Mo, Zhaohui, Zhu, Yikun, Lin, Jingna, Liu, Jie, Jia, Ying, Liu, Li, Ding, Ke, Xu, Michael, Zhou, Zhiguang |
|---|---|
| Zdroj: | In The Lancet Regional Health - Western Pacific June 2024 47 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|